SCHEMBL2270946

SCHEMBL2270946

O=C(Nc1cc(-c2cc(Cl)ccc2F)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 5/20 0.62
ACLY P53396 3/20 0.60
GRIK1 P39086 4/20 0.56
SUCNR1 Q9BXA5 1/20 0.55
KCNK2 O95069 1/20 0.54
KCNK10 P57789 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
PKM P14618 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
AKR1C4 P17516 1/20 0.52
AKR1C3 P42330 1/20 0.52
AKR1C2 P52895 1/20 0.52
AKR1C1 Q04828 1/20 0.52
KCNMA1 Q12791 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274304 0.89 ACLY (0.55) SERPINE1ACLYGRIK1SUCNR1KCNK2
SCHEMBL2272873 0.89 SERPINE1 (0.63) SERPINE1ACLYGRIK1SUCNR1MEN1
SCHEMBL2270359 0.87 MEN1 (0.57) SERPINE1ACLYGRIK1MEN1KMT2A
SCHEMBL2272986 0.87 SERPINE1 (0.60) SERPINE1ACLYGRIK1SUCNR1KCNK2
SCHEMBL5146969 0.86 SERPINE1 (0.63) SERPINE1ACLYGRIK1SUCNR1MEN1
SCHEMBL2269869 0.85 ACLY (0.67) SERPINE1ACLYGRIK1SUCNR1KCNK2
SCHEMBL2272049 0.84 ACLY (0.78) SERPINE1ACLYGRIK1SUCNR1MEN1
SCHEMBL1310106 0.84 GRIK1 (0.74) SERPINE1ACLYGRIK1SUCNR1KCNK2
SCHEMBL2276597 0.84 MEN1 (0.61) SERPINE1ACLYGRIK1SUCNR1MEN1
SCHEMBL27696818 0.84 SERPINE1 (0.57) SERPINE1ACLYGRIK1SUCNR1KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885ACLY 653/4885GRIK1 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.